JAK2 and essential thrombocythemia: A study that was conducted on 1099 patients who had primary or secondary MF demonstrated analogous results, namely that the median JAK2 V617F allele burden in the post-PV MF cohort was 86% vs. 58% in the post-ET MF cohort vs. 47% in the PMF cohort [6].